Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
04 2020
Historique:
received: 08 03 2019
accepted: 15 01 2020
entrez: 15 4 2020
pubmed: 15 4 2020
medline: 16 12 2020
Statut: epublish

Résumé

The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the rationale for the clinical use of LSD1 inhibitors. In acute promyelocytic leukemia (APL), pharmacological doses of retinoic acid (RA) induce differentiation of APL cells, triggering degradation of the PML-RAR oncogene. APL cells are resistant to LSD1 inhibition or knockout, but targeting LSD1 sensitizes them to physiological doses of RA without altering of PML-RAR levels, and extends survival of leukemic mice upon RA treatment. The combination of RA with LSD1 inhibition (or knockout) is also effective in other non-APL, acute myeloid leukemia (AML) cells. Nonenzymatic activities of LSD1 are essential to block differentiation, while RA with targeting of LSD1 releases a differentiation gene expression program, not strictly dependent on changes in histone H3K4 methylation. Integration of proteomic/epigenomic/mutational studies showed that LSD1 inhibitors alter the recruitment of LSD1-containing complexes to chromatin, inhibiting the interaction between LSD1 and the transcription factor GFI1.

Identifiants

pubmed: 32284990
doi: 10.1126/sciadv.aax2746
pii: aax2746
pmc: PMC7141832
doi:

Substances chimiques

Antineoplastic Agents 0
Histones 0
Oncogene Proteins, Fusion 0
PML-RARa bcr1 fusion protein, human 0
Tretinoin 5688UTC01R
Histone Demethylases EC 1.14.11.-
KDM1A protein, human EC 1.5.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eaax2746

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Références

J Biomol Screen. 2012 Jan;17(1):18-26
pubmed: 21965113
Cell Rep. 2018 Mar 27;22(13):3641-3659
pubmed: 29590629
J Am Chem Soc. 2010 May 19;132(19):6827-33
pubmed: 20415477
Mol Cell Proteomics. 2013 Mar;12(3):764-80
pubmed: 23319141
Blood. 2002 Oct 15;100(8):2989-95
pubmed: 12351412
Mol Cell Proteomics. 2002 May;1(5):376-86
pubmed: 12118079
Bioinformatics. 2008 Dec 15;24(24):2918-20
pubmed: 18945685
J Exp Med. 2013 Apr 8;210(4):647-53
pubmed: 23509325
Structure. 2011 Feb 9;19(2):212-20
pubmed: 21300290
Nat Cell Biol. 2016 Jan;18(1):21-32
pubmed: 26619147
EMBO J. 2010 Jun 2;29(11):1803-16
pubmed: 20389281
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Mol Cell. 2007 Aug 17;27(4):562-72
pubmed: 17707228
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Mol Cell Proteomics. 2015 Apr;14(4):1148-58
pubmed: 25680960
Cell. 2004 Dec 29;119(7):941-53
pubmed: 15620353
Cancer Cell. 2012 Apr 17;21(4):473-87
pubmed: 22464800
Nat Med. 2008 Dec;14(12):1333-42
pubmed: 19029980
Leukemia. 2010 Nov;24(11):1834-43
pubmed: 20861919
ACS Med Chem Lett. 2014 Dec 08;6(2):173-7
pubmed: 25699146
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Nat Med. 2012 Mar 11;18(4):605-11
pubmed: 22406747
Biol Direct. 2011 Oct 06;6:51
pubmed: 21978789
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Leukemia. 2019 Jun;33(6):1411-1426
pubmed: 30679800
Science. 2002 Feb 8;295(5557):1079-82
pubmed: 11834837
Cancer Cell. 2015 Jul 13;28(1):57-69
pubmed: 26175415
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
Eur J Cancer. 2009 May;45(7):1137-1145
pubmed: 19346125
Nat Protoc. 2006;1(6):2856-60
pubmed: 17406544
Blood. 2011 Jun 2;117(22):5795-802
pubmed: 21444912
Cancer Cell. 2010 Feb 17;17(2):173-85
pubmed: 20159609
Nat Rev Cancer. 2010 Nov;10(11):775-83
pubmed: 20966922
Nat Commun. 2019 Jan 18;10(1):332
pubmed: 30659187
Nat Cell Biol. 2011 Jun;13(6):652-9
pubmed: 21602794
Mol Cell Biol. 2010 Oct;30(20):4851-63
pubmed: 20713442
Leukemia. 2012 Sep;26(9):2039-51
pubmed: 22699452
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
FEBS Lett. 2005 Apr 11;579(10):2203-7
pubmed: 15811342
Blood. 2015 Dec 10;126(24):2561-9
pubmed: 26447191
J Med Chem. 2016 Feb 25;59(4):1501-17
pubmed: 26702542
Elife. 2013 Jun 18;2:e00633
pubmed: 23795291
Cancer Cell. 2018 Feb 12;33(2):322-336.e8
pubmed: 29438700
Cancer Res. 2016 Apr 1;76(7):1975-88
pubmed: 26837761

Auteurs

Roberto Ravasio (R)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.

Elena Ceccacci (E)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.

Luciano Nicosia (L)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.

Amir Hosseini (A)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.

Pier Luigi Rossi (PL)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.

Iros Barozzi (I)

Department of Surgery and Cancer, Imperial College London, Hammersmith, London W12, UK.

Lorenzo Fornasari (L)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.
EryDel SpA, Via Meucci 3, 20091 Bresso (MI), Italy.

Roberto Dal Zuffo (RD)

Experimental Therapeutics Program, FIRC Institute of Molecular Oncology Foundation (IFOM), Via Adamello 16, Milan 20139, Italy.

Sergio Valente (S)

Department of Drug Chemistry and Technologies, Pasteur Institute Italy, Cenci Bolognetti Foundation, Sapienza University of Rome, Rome, Italy.

Rossella Fioravanti (R)

Department of Drug Chemistry and Technologies, Pasteur Institute Italy, Cenci Bolognetti Foundation, Sapienza University of Rome, Rome, Italy.

Ciro Mercurio (C)

Experimental Therapeutics Program, FIRC Institute of Molecular Oncology Foundation (IFOM), Via Adamello 16, Milan 20139, Italy.

Mario Varasi (M)

Experimental Therapeutics Program, FIRC Institute of Molecular Oncology Foundation (IFOM), Via Adamello 16, Milan 20139, Italy.

Andrea Mattevi (A)

Department of Biology and Biotechnology, University of Pavia, Via Ferrata 9, 27100 Pavia, Italy.

Antonello Mai (A)

Department of Drug Chemistry and Technologies, Pasteur Institute Italy, Cenci Bolognetti Foundation, Sapienza University of Rome, Rome, Italy.

Giulio Pavesi (G)

Department of Biosciences, University of Milan, Milan 20133, Italy.

Tiziana Bonaldi (T)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.

Saverio Minucci (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.
Department of Biosciences, University of Milan, Milan 20133, Italy.
New Drugs Program, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH